Cingulate Inc (CING NASDAQ) stock market data APIs
$5.3351
-0.2(-3.7%)
as of May 6, 2026
Try our APIs with
free plan!
Cingulate Inc Financial Data Overview
Price chart is built with
Anychart
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Prev. Close
5.3351
Open
5.1325
High
5.39
Low
5.0812
52 wk Range
3.2-11.89
Market Cap
65 296 K
Shares Outstanding
12 251 K
EPS
-0.84
Beta
-0.813
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cingulate Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cingulate Inc data using free add-ons & libraries
Get Cingulate Inc Fundamental Data
Cingulate Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -19 397 214
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-18
- EPS/Forecast: -1.55
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cingulate Inc News
New
Biotech Stocks Facing FDA Decision In May 2026
(RTTNews) - In the U.S., May is observed as Mental Health Awareness Month, a tradition that goes back to 1949. About 60 million American adults live with some form of mental illness, ranging from mild...
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever
Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the rece...
Cingulate price target lowered to $16 from $17 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and keeps a Buy rating on the shares after meeting with its management to discuss Q3 re...
CING: Third Quarter Results
By John Vandermosten, CFA NASDAQ:CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ:CING) reported third quarter 2025 results on November 13th, 2025. No revenues were recorded and oper...
Get Cingulate Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
